| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:45 UTC |
|---|
| HMDB ID | HMDB0014808 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Pirenzepine |
|---|
| Description | Pirenzepine, also known as ulcoprotect or gastrozepin, belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine. Pirenzepine is a drug which is used for the treatment of peptic ulcer, gastric ulcer, and duodenal ulcer. It is in a class of drugs known as muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), resulting in an increase in gastric motility and digestion; whereas pirenzepine would inhibit these actions and cause decreased gastric motility leading to delayed gastric emptying and constipation. Pirenzepine is a very strong basic compound (based on its pKa). In humans, pirenzepine is involved in pirenzepine action pathway. Pirenzepine has been investigated for use in myopia control. Pirenzepine (Gastrozepin), an M1 selective antagonist, is used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It promotes the homodimerization or oligomerisation of M1 receptors. It has no effects on the brain and spinal cord as it cannot diffuse through the blood–brain barrier. |
|---|
| Structure | CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1 InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26) |
|---|
| Synonyms | | Value | Source |
|---|
| 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one | ChEBI | | Pirenzepina | ChEBI | | Pirenzepinum | ChEBI | | Dihydrochloride, pirenzepine | HMDB | | Ulcoprotect | HMDB | | Dolorgiet brand OF pirenzepine dihydrochloride | HMDB | | Gastrozepin | HMDB | | Piren basan | HMDB | | Piren-basan | HMDB | | Pirenzepin ratiopharm | HMDB | | Pirenzepin-ratiopharm | HMDB | | Pirenzepine dihydrochloride | HMDB | | Gastrotsepin | HMDB | | Pirenzepin | HMDB | | Ulgescum | HMDB | | CT-Arzneimittel brand OF pirenzepine dihydrochloride | HMDB | | Pirenzepin von CT | HMDB | | Ratiopharm brand OF pirenzepine dihydrochloride | HMDB | | Azupharma brand OF pirenzepine dihydrochloride | HMDB | | Boehringer ingelheim brand OF pirenzepine dihydrochloride | HMDB | | L-S 519 | HMDB | | Pyrenzepine | HMDB | | Sagitta brand OF pirenzepine dihydrochloride | HMDB | | Von CT, pirenzepin | HMDB |
|
|---|
| Chemical Formula | C19H21N5O2 |
|---|
| Average Molecular Weight | 351.4023 |
|---|
| Monoisotopic Molecular Weight | 351.169524941 |
|---|
| IUPAC Name | 2-[2-(4-methylpiperazin-1-yl)acetyl]-2,4,9-triazatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one |
|---|
| Traditional Name | pirenzepine |
|---|
| CAS Registry Number | 28797-61-7 |
|---|
| SMILES | CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1 |
|---|
| InChI Identifier | InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26) |
|---|
| InChI Key | RMHMFHUVIITRHF-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzodiazepines |
|---|
| Sub Class | 1,4-benzodiazepines |
|---|
| Direct Parent | 1,4-benzodiazepines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Pyrido-para-diazepine
- 1,4-benzodiazepine
- Alpha-amino acid or derivatives
- N-piperazineacetamide
- N-methylpiperazine
- N-alkylpiperazine
- 1,4-diazinane
- Piperazine
- Pyridine
- Imidolactam
- Benzenoid
- Heteroaromatic compound
- Cyclic carboximidic acid
- Tertiary carboxylic acid amide
- Amino acid or derivatives
- Carboxamide group
- Tertiary amine
- Tertiary aliphatic amine
- Azacycle
- Carboxylic acid derivative
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organic nitrogen compound
- Organic oxygen compound
- Organooxygen compound
- Organonitrogen compound
- Amine
- Hydrocarbon derivative
- Organic oxide
- Carbonyl group
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.68 g/L | Not Available | | LogP | 0.6 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.91 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.7895 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.08 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 268.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 537.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 200.7 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 85.3 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 155.1 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 47.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 220.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 359.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 724.9 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 614.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 54.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 864.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 182.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 224.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 464.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 413.7 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 318.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Pirenzepine,1TMS,isomer #1 | CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)N([Si](C)(C)C)C3=CC=CN=C32)CC1 | 2846.4 | Semi standard non polar | 33892256 | | Pirenzepine,1TMS,isomer #1 | CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)N([Si](C)(C)C)C3=CC=CN=C32)CC1 | 2924.1 | Standard non polar | 33892256 | | Pirenzepine,1TMS,isomer #1 | CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)N([Si](C)(C)C)C3=CC=CN=C32)CC1 | 4326.0 | Standard polar | 33892256 | | Pirenzepine,1TBDMS,isomer #1 | CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=CN=C32)CC1 | 3033.5 | Semi standard non polar | 33892256 | | Pirenzepine,1TBDMS,isomer #1 | CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=CN=C32)CC1 | 3129.6 | Standard non polar | 33892256 | | Pirenzepine,1TBDMS,isomer #1 | CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)N([Si](C)(C)C(C)(C)C)C3=CC=CN=C32)CC1 | 4385.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Pirenzepine GC-MS (Non-derivatized) - 70eV, Positive | splash10-03di-9274000000-86b6dd314412cb49103e | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Pirenzepine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Pirenzepine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 10V, Positive-QTOF | splash10-0ik9-0869000000-07871a195a1b07560aaf | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 20V, Positive-QTOF | splash10-03di-2920000000-f203c4e307f7cbb9ccba | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 40V, Positive-QTOF | splash10-01ox-9730000000-81e7602ee0e57b11f329 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 10V, Negative-QTOF | splash10-0udi-0039000000-eba2d6236adedf16c650 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 20V, Negative-QTOF | splash10-0ik9-0295000000-d2fe7d74f38b69f23111 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 40V, Negative-QTOF | splash10-03xr-1960000000-11b9714bc5655d979a4f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 10V, Positive-QTOF | splash10-0udi-0209000000-abe020ee7c3bd795b260 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 20V, Positive-QTOF | splash10-0w29-1429000000-17de4fa81cf69470057b | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 40V, Positive-QTOF | splash10-03kc-9230000000-b37f79f5ccdc399c3a22 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 10V, Negative-QTOF | splash10-0udi-0029000000-6d0cde8b33849d6a8df7 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 20V, Negative-QTOF | splash10-0w29-0059000000-c5eade40c8f67c093c19 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Pirenzepine 40V, Negative-QTOF | splash10-0bt9-0090000000-ca4cb52f06eeaadb0754 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|